NICE: its influence in treating osteoporosis in the UK and beyond

Compston, J. (in press) Recent advances in the management of osteoporosis. J R Coll Physicians.

Compston, J. , Cooper, A. , Cooper, C. , Francis, R. , Kanis, J.A. , Marsh, D. et al. (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62: 105-108.

Dawson-Hughes, B. , Tosteson, A.N. , Melton 3rd, L.J. , Baim, S. , Favus, M.J. , Khosla, S. et al. (2008) National Osteoporosis Foundation Guide Committee (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19: 449-458.

Delmas, P.D. and Siris, E.S. ( 2008) NICE recommendations for the prevention of osteoporotic fractures in postmenopausal women. Bone 42: 16-18.

Dolan, P. and Torgerson, D.J. ( 2000) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 11: 551-552.

Kanis, J.A. on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK.

Kanis, J.A. and Compston, J.E. ( 2008) NICE continues to muddy the waters of osteoporosis. Osteoporos Int 19: 1105-1107.

Kanis, J.A. , Johansson, H. , Oden, A. , Johnell, O. , De Laet, C. , Melton, L.J. et al. (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19: 893-899.

Kanis, J.A. , Johansson, H. , Johnell, O. , Oden, A. , De Laet, C. , Eisman, J. et al. (2005a) Alcohol intake as a risk factor for fracture . Osteoporos Int 16: 737-742.

Kanis, J.A. , Johnell, O. , Oden, A. , Johansson, H. , De Laet, C. , Eisman, J. et al. (2005b) Smoking and fracture risk: a meta-analysis . Osteoporos Int 16: 222-228.

Kanis, J.A. , Johnell, O. , Oden, A. , Johansson, H. and McCloskey, E. ( 2008a) FRAXTM and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385-397.

Kanis, J.A. , Adams, J. , Borgström, F. , Cooper, C. , Jönsson, B. , Preedy, D. et al. (2008b) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42: 4-15.

Kanis, J.A. , McCloskey, E.V. , Johansson, H. , Strom, O. , Borgstrom, F. and Oden, A. and the National Osteoporosis Guideline Group. ( 2008c) Case finding for the management of osteoporosis with FRAXTM - assessment and intervention thresholds for the UK. Osteoporos Int 19: 1395-1408.

Kanis, J.A. , Burlet, N. , Cooper, C. , Delmas, P.D. , Reginster, J.Y. , Borgström, F. et al. on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). ( 2008d) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19: 399-428.

National Institute for Health and Clinical Excellence. Final appraisal determination. (2005) Alendronate, etidronate, risedronate and raloxifene for the secondary prevention of osteoporotic fragility fractures in postmenopausal women, NICE: London.

National Institute for Health and Clinical Excellence. ( 2008a) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (2008), NICE: London.

National Institute for Health and Clinical Excellence. ( 2008b) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women, NICE: London.

Poole, K.E. and Compston, J.E. ( 2006) Osteoporosis and its management. Brit Med J 333: 1251-1256.

The Independent, 11 March 1995, UK.